Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.5K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.8K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
High-Performance Liquid Chromatography: Introduction01:11

High-Performance Liquid Chromatography: Introduction

2.6K
High-performance liquid chromatography(HPLC), formerly referred to as High-pressure liquid chromatography, is a powerful technique used to separate, identify, and quantify components in complex mixtures. The term "high pressure" refers to using high pressure to push the liquid mobile phase through the tightly packed columns.
In HPLC, two phases play a critical role in the separation process:
2.6K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K
Three-Dimensional Microscopy in Microbiology01:28

Three-Dimensional Microscopy in Microbiology

452
Three-dimensional imaging techniques are essential in cell biology, allowing researchers to visualize intricate cellular structures with high resolution. Two prominent methods, Differential Interference Contrast Microscopy (DIC) and Confocal Scanning Laser Microscopy (CSLM), provide distinct advantages for imaging live and thick specimens, respectively.Differential Interference Contrast MicroscopyDIC microscopy enhances contrast in transparent, unstained samples by converting phase...
452
Basal Lamina are the Specialized Form of ECM01:03

Basal Lamina are the Specialized Form of ECM

3.1K
The basal lamina is a thin extracellular layer that lies underneath the cells and separates them from other tissues. The three layers of the basal lamina are lamina lucida, lamina densa and lamina reticularis. The basal lamina, a mixture of glycoproteins and collagen, provides an attachment site for the epithelium, separating it from underlying connective tissue. The framework of basal lamina has other essential proteins such as laminins mesh, perlecan, entactin, and type IV collagen.
Proteins...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 'Bermuda Triangle' Effect Shaping Reef Fish Connectivity Across the Western Atlantic.

Molecular ecology·2026
Same author

Insights into Sudbury's deep architecture: a revised geodynamic model for Earth's largest ore-bearing impact structure.

Scientific reports·2026
Same author

Emergent anisotropic three-phase order in critically doped superconducting diamond films.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Clinical Uses Of Long-Duration Ultrasound And Long-Duration Sonophoresis In Sports Medicine - Minireview.

Journal of orthopaedics (Chesterton, Ind.)·2025
Same author

The influence of body mass index on airway resistance in children with sickle cell disease: A longitudinal study based on impulse oscillometry.

Respiratory medicine·2024
Same author

Bioprinted Human Lung Cancer-Mimics for Tissue Diagnostics Applications.

Tissue engineering. Part A·2023

Related Experiment Video

Updated: Oct 17, 2025

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.2K

CML Chapter.

David Snyder1

  • 1City of Hope Medical Center, 1500 E Duarte Rd., Duarte, CA, 91010, USA. dsnyder@coh.org.

Cancer Treatment and Research
|October 9, 2021
PubMed
Summary
This summary is machine-generated.

Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment, making it controllable with normal life expectancy. Management now focuses on quality of life and potential TKI discontinuation.

Keywords:
Chronic myelogenous leukemiaDrug discontinuationMajor molecular responseNCCN guidelinesSokal scoreTyrosine kinase inhibitors

More Related Videos

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.0K
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

13.9K

Related Experiment Videos

Last Updated: Oct 17, 2025

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.2K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.0K
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

13.9K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • The discovery of imatinib revolutionized chronic myeloid leukemia (CML) treatment.
  • Before TKIs, allogeneic hematopoietic cell transplantation (HCT) was the primary upfront therapy for CML.
  • CML is caused by the Philadelphia Chromosome leading to the BCR-ABL fusion gene.

Purpose of the Study:

  • To highlight key issues in managing CML patients in the post-TKI era.
  • To discuss the shift from HCT to targeted TKI therapy.
  • To emphasize the improved prognosis and quality of life for CML patients.

Main Methods:

  • Review of treatment evolution in CML.
  • Analysis of the impact of TKIs (imatinib, dasatinib, nilotinib, bosutinib).
  • Case-based discussion of CML management challenges.

Main Results:

  • TKIs have made CML a controllable disease with near-normal life expectancy.
  • HCT is rarely used upfront for newly diagnosed CML patients.
  • Personalized medicine approach in CML serves as a model for other cancers.

Conclusions:

  • CML management has shifted to targeted therapy with TKIs, significantly improving patient outcomes.
  • Quality of life, including potential for pregnancy and TKI discontinuation, is a key goal.
  • The management of CML exemplifies successful targeted therapy in oncology.